ecallen, Author at Zom•Dx

Veterinarian Examining Beagle in Veterinary Clinic Setting

02/02/2026

How Contactless Monitoring Technology is Transforming Veterinary Care

Veterinary medicine is embracing innovation at an unprecedented pace, and one of the most transformative technologies to emerge is contactless vital signs monitoring. Traditionally, measuring heart rate, respiratory rate, and temperature requires physical contact—often causing stress for pets and consuming valuable time for veterinary teams. Contactless monitoring changes this dynamic by enabling accurate, noninvasive measurement of vital signs without touching the animal. This advancement is revolutionizing patient care, improving efficiency, and enhancing the overall veterinary experience.

The stress-reduction benefits of contactless monitoring extend across all companion animal species. Cats, which often experience significant stress from restraint and handling in clinical settings, benefit particularly from monitoring methods that don’t require direct contact. Exotic pets—including rabbits, birds, and reptiles—can be monitored more safely without the risks associated with manual restraint of fragile or easily stressed species. Even cooperative canine patients benefit from the streamlined workflow that contactless systems provide during routine wellness examinations.

What is Contactless Monitoring for Veterinary Patients?

Contactless monitoring uses advanced sensors and imaging technologies to measure physiological parameters without direct physical interaction. Methods include:

Thermal imaging: Detect body temperature through heat signatures
Radar and LiDAR sensors: Measure micromovements associated with breathing and heart rate
Computer vision and AI: Analyze subtle changes in body posture, chest movement, and facial cues to interpret animal status

These contactless monitoring systems vary in complexity and application. Some platforms offer real-time continuous surveillance suitable for intensive care units and recovery areas, while others provide on-demand vital signs collection during routine examinations. The technology can be adapted to different clinical environments—from traditional exam rooms to isolation wards where minimizing staff entry is critical. As these systems become more sophisticated, they’re increasingly capable of monitoring multiple patients simultaneously, making them practical even for busy multi-doctor practices.

Clinical Benefits of Contactless Monitoring in Veterinary Practice

Animals often experience stress during veterinary visits, which can skew vital signs and complicate diagnosis. Contactless monitoring helps address these challenges by:

Reducing stress caused by restraint or invasive probes
Improving accuracy by capturing data while patients remain calm
Enhancing safety by minimizing the risk of injury to staff and patients
Saving valuable time by streamlining clinical workflows

This technology proves particularly valuable for feline patients, exotic species, and any animals that become aggressive or fearful when handled. Traditional vital signs collection often requires multiple staff members to restrain anxious patients, which can elevate heart rate and respiratory rate—the very parameters being measured. Contactless systems eliminate this paradox by allowing animals to remain in a relatively calm state during data collection. For veterinary technicians and assistants who face injury risk from fractious patients, contactless monitoring also represents a meaningful safety improvement that can reduce workplace injuries and associated costs.

The benefits extend beyond the clinic, improving the overall experience for pet owners while supporting better patient outcomes, early detection of health concerns, and improved operational efficiency for veterinary teams.

Practical Applications of Contactless Monitoring Technology

There are several clinical applications for contactless monitoring in veterinary settings. Postsurgical recovery and critical care patients, in particular, can benefit from more frequent or continuous vital signs monitoring without disruption. Isolation wards offer another valuable use case, with the potential to reduce staff exposure and lower PPE costs. Overnight monitoring—especially in rural or understaffed clinics—can be enhanced through imaging-based systems and smart device alerts that provide peace of mind and rapid response capabilities.

In post-surgical settings, contactless monitoring technology allows veterinary teams to track recovery patterns without repeatedly disturbing anesthetized or painful patients. Animals recovering from procedures can rest undisturbed while staff receive continuous or interval updates on vital signs, enabling early detection of complications like hypothermia, respiratory depression, or emerging cardiovascular concerns. This hands-off approach is especially beneficial for orthopedic surgery patients where minimizing movement during initial recovery is critical.

For isolation ward applications, the technology offers dual benefits: protecting staff from infectious disease exposure while ensuring patients receive adequate monitoring despite limited direct contact. During disease outbreaks or when managing highly contagious cases, contactless systems enable vital signs collection without the time, expense, and environmental impact of repeatedly donning and doffing protective equipment. Emergency and specialty hospitals managing infectious disease cases have found this capability particularly valuable for maintaining both biosecurity protocols and high standards of patient monitoring.

Implementation Considerations for Veterinary Practices

While promising, contactless monitoring does come with practical considerations that veterinary practices should evaluate before implementation:

Cost and accessibility: Advanced sensors may represent a significant initial investment. Practices need to assess how these systems will integrate with existing practice management software and medical records platforms, which may require additional technical infrastructure or IT support.
Training requirements: Practices need to assess how these systems will integrate with existing practice management software and medical records platforms, which may require additional technical infrastructure or IT support.
Environmental factors: Lighting conditions, patient movement, and positioning can impact readings. Certain patients may present additional challenges—heavily coated breeds, very small animals, or patients with specific coat colors can sometimes interfere with sensor readings. For these reasons, practices should maintain traditional monitoring capabilities as backup methods when contactless systems may not provide reliable data.

The Future of Contactless Veterinary Monitoring Technology

Despite these challenges, contactless vital signs monitoring represents far more than convenience—it is a meaningful leap forward in veterinary care. By reducing stress, improving accuracy, and enabling proactive health management, this technology strengthens the human-animal bond and elevates the standard of care. As adoption continues to grow, veterinarians who embrace these tools will be well positioned to lead the future of compassionate, efficient, and cutting-edge medicine.

LEARN MORE

10/03/2025

ecallenPost-OpVETIGEL

Modern vs Traditional Hemostatic Agents: Which Works Best for Your Veterinary Practice?

Based on the continuing education webinar presented by Ann Marie Woyma, DVM.*

Surgical bleeding remains one of the most significant challenges facing veterinary practitioners. Extended bleeding episodes increase anesthesia duration, elevate patient risk, and can transform routine procedures into complex cases requiring emergency intervention.

Despite advances in surgical techniques, hemostatic control continues to rely heavily on methods developed decades ago. Recent developments in polymer-based hemostatic technology like Vetigel® hemostatic gel offer new approaches, but how do they compare to established methods?

How Do Traditional and Modern Hemostatic Agents Work?

Veterinary practitioners have multiple hemostatic approaches available, each with distinct mechanisms of action. Understanding these differences is essential for selecting the right product for each clinical scenario.

Traditional Matrix-Based Hemostatic Agents

Cellulose-based products, gelatin sponges, and collagen matrices provide scaffolding for natural clot formation through the patient’s coagulation cascade.

Advantages: Well-established safety profile, cost-effective for routine procedures, familiar to most practitioners

Limitations: Requires direct blood contact for activation, integrates with patient’s clot (removal disrupts hemostasis), variable effectiveness with high-pressure bleeding, can impair surgical visualization

Modern Polymer-Based Hemostatic Technology

Plant-based polymers like Vetigel hemostatic gel create mechanical barriers through ionic crosslinking, independent of natural clotting mechanisms.

Advantages: Immediate hemostatic effect regardless of patient coagulation status, non-integrating (removable without disturbing hemostasis), effective against high-pressure arterial bleeding, maintains clear surgical field

Limitations: Higher cost per application, requires specific application technique, limited long-term comparative studies

Clinical Evidence: A study comparing polymer-based agents like the Vetigel product showed 94% immediate hemostasis rates compared to 67% for traditional matrix agents in high-pressure bleeding scenarios.

Which Hemostatic Agent Should You Choose for Different Species?

Species-specific factors significantly impact hemostatic agent selection and effectiveness in veterinary surgery.

Canine Surgical Bleeding Control

Dogs tolerate most hemostatic agents well, but patient size impacts cost-effectiveness. Large breed surgical procedures may require multiple applications of any hemostatic product.

Feline Surgical Considerations

Cats show particular sensitivity to prolonged anesthesia, making rapid hemostasis especially critical. Smaller surgical sites may favor precision-application products over broad-coverage traditional agents.

Exotic Animal Hemostasis

Limited research exists on hemostatic agent safety in exotic species. Consultation with exotic veterinary specialists is recommended when considering newer technologies.

What Are the Best Hemostatic Agents for Common Veterinary Procedures?

Matching the right hemostatic technology to specific surgical procedures maximizes both clinical outcomes and cost-effectiveness.

Enucleation Surgery Bleeding Control

Clinical Comparison: Average procedure time with traditional methods (45-60 minutes) versus Vetigel hemostatic gel polymer technology (35-45 minutes). Post-operative complications: Traditional approach (15% discharge issues) versus Vetigel product-based hemostasis (3% discharge issues) when properly removed.

Economic Analysis: Higher product cost is offset by reduced anesthesia time and fewer complications.

Dental Extraction Bleeding Control

Extraction sites in highly vascular oral tissue present difficult access for traditional ligation. Full-mouth extractions show 30% reduction in total anesthesia time with advanced hemostatic protocols using products like Vetigel hemostatic gel.

Mass Removal and Soft Tissue Surgery

Small masses: Traditional methods often sufficient Large masses/mastectomies: Advanced agents like Vetigel hemostatic gel provide better coverage Vascular masses: The Vetigel product shows superior high-pressure bleeding control.

When Should Your Practice Use Traditional vs Modern Hemostatic Agents?

Developing clear selection criteria helps optimize both clinical outcomes and practice profitability based on case-specific factors.

When Traditional Methods Remain Optimal:

Routine procedures with minimal bleeding expected
Cost-sensitive cases where bleeding is easily controlled

When Advanced Technology Provides Value:

High-risk patients who cannot tolerate blood loss
Procedures with historically difficult hemostatic control
Emergency situations requiring immediate bleeding cessation
Cases where surgical visualization is critical
Coagulopathic patients or those on anticoagulants

Products like Vetigel hemostatic gel excel in these scenarios due to their coagulation-independent mechanism and rapid action.

Economic Considerations by Practice Type:

High-Volume/Low-Cost Practices: Traditional agents for routine cases, Vetigel hemostatic gel for complications
Specialty Practices: The Vetigel product as standard for complex procedures
Emergency Clinics: Stock both options based on case severity assessment

How to Successfully Integrate Modern Hemostatic Agents into Your Practice

Transitioning to advanced hemostatic technology requires systematic implementation rather than wholesale practice changes. This phased approach maximizes success while controlling costs.

Phase 1: Assessment (Months 1-2)

Audit current hemostatic challenges in your practice. Calculate true cost of extended procedures due to bleeding complications. Identify 2-3 procedure types for initial trial.

Phase 2: Selective Implementation (Months 3-6)

Train team on proper application techniques for Vetigel hemostatic gel. Use advanced products for pre-identified challenging cases. Document outcomes and time savings.

Phase 3: Protocol Development (Months 6-12)

Establish clear criteria for product selection. Develop cost-effective protocols based on case type. Train entire surgical team on decision matrix.

What Clinical Evidence Should Guide Your Decisions?

Evidence-based hemostatic agent selection requires tracking specific metrics in your own practice to inform product decisions.

Track These Clinical Efficacy Metrics:

Time to hemostasis achievement
Total surgical duration
Post-operative bleeding complications
Patient recovery indicators

Assess Economic Impact:

Product cost per procedure
Anesthesia time savings value
Complication reduction cost benefit
Overall procedure profitability impact

Real-World Results: Multi-Modal Approach Case Study

A 1,200-case veterinary facility implemented a tiered hemostatic protocol:

Protocol: Routine procedures used traditional matrix agents, complex/high-risk cases used Vetigel hemostatic gel polymer technology, emergency bleeding received immediate Vetigel product deployment.

Results After 12 Months: 23% reduction in average surgical time for complex cases, 67% decrease in post-operative bleeding complications, 15% improvement in surgical suite efficiency, positive ROI achieved within 8 months.

Making Smart Hemostatic Decisions for Your Practice

Modern hemostatic technology offers genuine advantages for specific clinical scenarios, but success requires thoughtful integration rather than wholesale replacement of established methods. The key lies in matching the right technology to the right clinical situation while considering both medical and economic factors.

Practices that develop systematic approaches to hemostatic product selection report improved surgical efficiency, reduced complications, and enhanced team confidence in managing bleeding challenges.

Ready to optimize surgical bleeding control in your practice?

Contact us to learn more about implementing evidence-based hemostatic protocols.

*Dr. Wyoma was paid by Zomedica, Inc. for presenting this webinar. Watch the full presentation here.

Vetigel is a registered trademark of Cresilon, Inc.

LEARN MORE

10/02/2025

ecallenFeline HealthTRUFORMA

Diagnosing Feline Hyperthyroidism: Why the TRUFORMA® Biosensor Testing Platform’s Feline TSH Test Outperforms Traditional Methods

Based on the continuing education webinar presented by Dr. Kristin Marzin, DVM*

Feline hyperthyroidism affects 10% of geriatric cats, making it the most common endocrine disorder in veterinary medicine. Yet for many practitioners, diagnosing borderline cases remains frustratingly difficult. Does this scenario sound familiar? You have a 12-year-old cat with weight loss and a palpable thyroid nodule, but the T4 comes back normal. Do you treat? Wait and retest? Send out for more diagnostics and wait days for results?

Traditional testing methods leave veterinarians in diagnostic gray zones far too often—and waiting for send-out labs delays treatment decisions. The TRUFORMA® platform’s feline-specific TSH test changes that, offering the sensitivity and specificity needed to confidently diagnose hyperthyroidism in 20 minutes, right in your clinic.

The Problem: Total T4 Testing Misses Up to 10% of Hyperthyroid Cats

While approximately 90% of hyperthyroid cats can be diagnosed through clinical signs and elevated T4, a significant percentage of cases fall into diagnostic gray zones. Several factors complicate diagnosis:

Early disease stages where T4 values haven’t elevated yet
Normal T4 fluctuations that may drift in and out of reference ranges
Non-thyroidal illness that can suppress T4 values into normal ranges

The 2016 AAFP guidelines for hyperthyroid management organize these challenging cases into six categories, with most requiring either repeated T4 testing or additional thyroid hormone testing to confirm or exclude hyperthyroidism.

Why Free T4 Falls Short in Real-World Practice

Traditionally, free T4 (measured by equilibrium dialysis) has been used to support hyperthyroid diagnosis in cats, offering nearly 99% sensitivity. However, this highly sensitive test has limitations:

Free T4 can be normal, increased, or decreased in cats with non-thyroidal illness
Should not be used as the sole confirmatory test
Newer chemiluminescent methods show questionable accuracy, consistently undervaluing results compared to equilibrium dialysis
Not recommended for monitoring cats following radioactive iodine therapy

Feline TSH vs. Canine TSH: Why Species-Specific Testing Matters

In hyperthyroid cats, autonomously secreted thyroid hormones suppress TSH production to near-zero levels—a finding that should make TSH testing ideal for diagnosis. The problem? Canine TSH assays weren’t designed for feline physiology.

Normal feline TSH range is often lower than the canine assay’s lower limit of quantification
Canine TSH cannot reliably differentiate between healthy cats and those with non-thyroidal illness
Cannot be used as a sole diagnostic test

Despite these limitations, research by Dr. Mark Peterson’s group examining 917 hyperthyroid cats demonstrated that serum TSH concentrations are suppressed in 98% of hyperthyroid cats, with median TSH below 0.03 ng/mL compared to 0.05 ng/mL in clinically normal cats. The study found that only 2% of hyperthyroid cats had measurable canine TSH concentrations, while nearly 70% of euthyroid cats had detectable levels. This meant that finding a measurable canine TSH could help rule out hyperthyroidism in cats, though the test showed poor specificity (69.9%) when used alone.

The key insight: while canine TSH could be somewhat useful for screening, its lack of sensitivity in the low range where feline values typically fall—combined with poor specificity—highlighted the critical need for a feline-optimized assay.

How the TRUFORMA® Platform's Feline TSH Test Solves the Diagnostic Puzzle

Zomedica developed the TRUFORMA biosensor testing platform’s feline-verified TSH test to address every limitation of canine assays—with technology optimized specifically for feline physiology and delivered through the only in-clinic platform available. Here’s what makes the TRUFORMA® platform test different:

The Only In-Clinic Feline TSH Test Available

The TRUFORMA system is the only point-of-care platform offering feline-specific TSH testing. Get accurate results in 20 minutes—no send-outs, no waiting, no delayed treatment decisions. Diagnose and create treatment plans in the same appointment, improving both patient outcomes and client satisfaction.

3X More Sensitive Than Canine TSH

The TRUFORMA platform’s feline TSH test has a lower limit of detection of 0.008 ng/mL compared to 0.03 ng/mL for canine TSH—providing the precision needed to accurately measure feline TSH values in the critical low range where feline physiology operates.

Prevents Misdiagnosis in 12% of Healthy Cats

TRUFORMA platform test clinical data from 170 feline samples revealed:

95% of healthy cats had serum TSH above 0.01 ng/mL
93% of hyperthyroid cats had TSH below 0.01 ng/mL
12% of normal cats tested below the canine assay’s detection limit but had measurable TSH with the TRUFORMA platform test—preventing false positive diagnoses and unnecessary treatment

Proven Precision You Can Trust

The TRUFORMA platform’s multi-instrument testing showed coefficient of variation less than 10%—2.5X better than industry standards—ensuring consistent, reliable results.

Critical Application: Detecting Iatrogenic Hypothyroidism

Here’s a sobering statistic: Nearly 50% of treated hyperthyroid cats develop iatrogenic hypothyroidism, regardless of treatment method. Even more concerning? T4 monitoring alone misses almost 80% of these cases.

Why does this matter for your patients?

Decreased GFR and progression to azotemic chronic kidney disease
50% shorter median survival time in cats that become azotemic
Subtle clinical signs easily missed or attributed to aging

The solution: The TRUFORMA platform’s T4 test and feline TSH test combination identifies these cases early. When you see low or low-normal T4 with elevated TSH, you can adjust methimazole doses or add thyroid supplementation before kidney damage progresses—all with same-day results that enable immediate intervention.

Catching Hyperthyroidism Earlier: The TRUFORMA Platform Advantage

Traditional send-out testing often catches hyperthyroidism only after significant organ damage has occurred—and delays treatment by days while you wait for results. The TRUFORMA biosensor testing platform changes this timeline by identifying cats in the earliest disease stages with same-appointment results, enabling intervention when it’s most effective and before irreversible complications develop.

Early detection means:

Prevention of cardiac remodeling and hypertension
Reduced risk of kidney damage from hyperfiltration
Better treatment outcomes with less aggressive intervention
Improved quality of life for your feline patients

The Research Behind the TRUFORMA Platform's Feline TSH Test

Recent peer-reviewed research published by Dr. Mark Peterson compared the TRUFORMA platform’s feline-optimized TSH assay with chemiluminescent canine TSH testing across multiple patient populations: hyperthyroid cats, radioiodine-treated cats, chronic kidney disease patients, and healthy cats.

The verdict? The TRUFORMA platform’s feline-specific test demonstrated superior sensitivity and specificity across all groups, offering a more practical alternative to thyroid scintigraphy for practices without nuclear medicine capabilities—with the critical advantage of in-clinic results in 20 minutes.

Implementing The TRUFORMA Biosensor Testing Platform in Your Practice

The TRUFORMA platform’s T4 + feline TSH is becoming the new diagnostic standard, replacing the T4/free T4 send-out combination for hyperthyroid workup. The TRUFORMA in-clinic biosensor testing platform offers value across your entire case management workflow:

✓ Initial diagnosis of suspected hyperthyroidism—results in 20 minutes

✓ Routine wellness screening in geriatric cats during annual exams

✓ Treatment monitoring to prevent iatrogenic hypothyroidism

✓ Differentiating subclinical hyperthyroidism from non-thyroidal illness

Same-day diagnosis means same-day treatment decisions—improving patient outcomes, increasing client satisfaction, and eliminating the frustration of waiting for send-out results while your patient continues to deteriorate.

Ready to bring same-day feline hyperthyroid diagnosis to your practice? The TRUFORMA in-clinic biosensor testing platform is the only point-of-care system offering feline-specific TSH testing. Get accurate results in 20 minutes and make confident treatment decisions in the same appointment.

*Dr. Marzin is a Zomedica Professional Services Veterinarian and was paid for this presentation. Watch the full presentation here.

LEARN MORE

09/25/2025

ecallenCanine HealthTRUFORMA

Canine Pancreatitis Diagnosis: Point-of-Care Testing Case Study

Acute pancreatitis in dogs can present with vague clinical signs that overlap with many gastrointestinal conditions, making rapid, accurate diagnosis challenging in general practice. This case study, provided by Dr. Deborah Greco, demonstrates how point-of-care pancreatic lipase testing using the TRUFORMA® diagnostic system enabled immediate diagnosis and successful outpatient management of acute pancreatitis in a 12-year-old Yorkshire Terrier, avoiding costly emergency referral while providing excellent patient care.

Case Presentation: Complex Medical History with Acute GI Signs

Patient Background

Signalment: 12-year-old spayed female Yorkshire Terrier named Lola

Presenting Complaints: Large bowel diarrhea with mucus, vomiting, anorexia, lethargy

Relevant Medical History:

Hypothyroidism (1 year duration) – managed with levothyroxine 0.2 mg BID
Hyperadrenocorticism (8 months duration) – treated with trilostane 20 mg BID
Atopic dermatitis – managed with monthly Cytopoint injections and topical therapy
Chronic GI sensitivity – maintained on hydrolyzed protein diet

Initial Clinical Course

Timeline of Events:

Day 1: Normal eating, then midnight vomiting followed by four episodes of mucoid diarrhea
Weekend: Owner initiated metronidazole, but patient stopped eating and drinking
Urgent care visit: Received maropitant, B12 injection, and Entyce
Presentation day: Continued anorexia, lethargy, weakness, and stumbling

Physical Examination Findings:

Dehydration: 5-6% based on tacky mucous membranes
Dermatologic lesions: Pyoderma on ventral abdomen and left neck
General condition: Lethargic and weak with unsteady gait
Otherwise unremarkable physical examination

Diagnostic Approach: Point-of-Care Testing Strategy

Laboratory Testing Protocol

Minimum Database Collected:

Complete blood count (CBC)
Comprehensive serum chemistry profile
TRUFORMA cPL (canine pancreatic lipase) – point-of-care testing

Key Laboratory Results

Hematology Findings (Suggesting Inflammation):

WBC: 11.60 K/µL (elevated, reference 5.05-16.76)
Monocytes: 1.18 K/µL (elevated, reference 0.16-1.12) – indicating inflammatory response
Platelets: 89 K/µL (thrombocytopenia, reference 148-484) – possible consumption
Neutrophils: 68.8% suggesting inflammatory process

Chemistry Profile Abnormalities:

ALT: 136 U/L (elevated, reference 10-125)
ALP: 399 U/L (elevated, reference 23-212)
BUN: 41 mg/dL (elevated, reference 7-27) – likely dehydration-related
Globulin: 5.0 g/dL (elevated, reference 2.5-4.5)
Cholesterol: 334 mg/dL (elevated, reference 110-320)

Critical Finding – TRUFORMA cPL Result:

Initial cPL: 1190 µg/L (significantly elevated)
Reference range: <200 µg/L normal, >400 µg/L consistent with pancreatitis

TRUFORMA Diagnostic System: Enabling Rapid Decision-Making

Point-of-Care Testing Advantages

Immediate Clinical Benefits:

15-minute results allowed same-visit treatment planning
Quantitative measurement provided baseline for monitoring therapy
Avoided referral delay and expense of emergency hospitalization
Enabled confident outpatient management with appropriate monitoring

Technology Advantages:

High accuracy correlating with Texas A&M Spec® cPL
User-friendly operation requiring minimal training
Consistent results allowing precise monitoring and unaffected by sample quality
Multi-test platform for comprehensive point-of-care diagnostics

Clinical Decision Impact

Immediate Treatment Decisions Based on Results:

Confirmed pancreatitis diagnosis justified specific dietary and medical management
Baseline cPL value established for therapeutic monitoring
Outpatient management deemed appropriate based on clinical status and owner compliance
Referral avoided saving client significant expense while maintaining quality care

Treatment Protocol and Monitoring Strategy

Initial Management Plan

Immediate Interventions:

Subcutaneous fluid therapy: 100 mL administered in-clinic
Home fluid therapy: Owner-administered SQ fluids for continued hydration
Dietary modification: Switched to Purina ProPlan EN gastroenteric low-fat diet
Medication adjustments: Discontinued metronidazole, continued trilostane and levothyroxine
Symptomatic support: Fortiflora prescribed for diarrhea management

Monitoring Protocol:

Serial cPL testing using TRUFORMA diagnostic system
Clinical assessment for appetite, hydration, and energy level
Owner communication for home monitoring and compliance

Treatment Response Monitoring

Day 3 Follow-up:

TRUFORMA cPL: Decreased to 900 µg/L (25% reduction)
Clinical improvement: Some appetite return, better hydration
Continued management: SQ fluids and dietary therapy

One Week Follow-up:

TRUFORMA cPL: Further decreased to 600 µg/L (50% reduction from initial)
Complications addressed: Worsening dermatitis managed with Cytopoint injection
Additional treatments: Enrofloxacin for pyoderma, Claro for otitis externa
Laboratory normalization: Liver enzymes and WBC returning to normal ranges

Eight Days Later:

TRUFORMA cPL: 314 µg/L (74% reduction from initial value)
Clinical resolution: Normal appetite, voluntary water consumption, excellent energy
Laboratory normalization: Complete resolution of liver enzyme elevation and leukocytosis
Full recovery: Patient returned to normal activity and demeanor

Case Study Analysis: Clinical Lessons

Diagnostic Value of Serial cPL Monitoring

Quantitative Trend Analysis:

Initial diagnosis: cPL 1190 µg/L confirmed acute pancreatitis
Early response: cPL 900 µg/L (Day 3) showed treatment effectiveness
Continued improvement: cPL 600 µg/L (Day 7) supported ongoing management
Near resolution: cPL 314 µg/L (Day 15) indicated successful treatment

Clinical Correlation: The consistent correlation between decreasing cPL values and clinical improvement validated the treatment approach and provided objective evidence of recovery progress.

Benefits of Point-of-Care Testing

Practice Management Advantages:

Immediate results enabled same-visit treatment planning
Cost-effective care avoided expensive emergency referral
Client confidence improved through rapid diagnosis and monitoring
Quality outcomes achieved through appropriate treatment and monitoring

Patient Care Benefits:

Rapid diagnosis prevented delayed treatment
Appropriate therapy initiated immediately based on objective data
Successful monitoring ensured treatment effectiveness
Outpatient management reduced stress and maintained quality of life

TRUFORMA Diagnostic System: Advanced Point-of-Care Technology

The TRUFORMA diagnostic system brings laboratory-quality pancreatic testing directly into veterinary clinics using innovative bulk acoustic wave technology. This advanced system provides quantitative cPL results in 15 minutes, enabling immediate diagnosis and treatment decisions for optimal patient care.

Key Technology Features:

15-minute turnaround time for immediate clinical decision-making
Bulk acoustic wave technology eliminates interference from hemolysis or lipemia
Quantitative results enable precise treatment monitoring and trend analysis
Reference laboratory correlation >0.95 for reliable accuracy
Multi-analyte platform supporting comprehensive diagnostic testing
Simple operation requiring minimal training for consistent results

Transform your practice’s diagnostic capabilities with rapid, accurate pancreatic testing that enables successful outpatient management of pancreatitis cases like demonstrated in this real-world case study provided by Dr. Deborah Greco.

Visit zomedicadev.com to discover how the TRUFORMA diagnostic system can revolutionize your approach to gastrointestinal disease diagnosis and management.

LEARN MORE

09/19/2025

ecallenPost-OpVETGuardian PLUS

Revolutionizing Veterinary Care: The Power of Continuous Vital Signs Monitoring

Post-operative monitoring represents one of the highest-risk periods in veterinary medicine, with up to 47% of anesthetic-related deaths in dogs and 60% in cats occurring during recovery. Traditional intermittent monitoring methods leave dangerous gaps in patient surveillance, particularly during the critical first three hours post-surgery. The VETGuardian® monitoring system revolutionizes veterinary patient care through continuous, non-contact vital signs monitoring that enhances safety while reducing staff workload.

The Critical Gap in Post-Operative Veterinary Monitoring

The transition from anesthesia to recovery creates a dangerous window of vulnerability. Despite consistent monitoring during surgical procedures, the recovery period is frequently marked by reduced vigilance and intermittent observation schedules.

Alarming Statistics:

47% of anesthetic-related deaths in dogs occur postoperatively
60% of anesthetic-related deaths in cats happen during recovery
First three hours represent the highest-risk period
10-15 minute monitoring intervals leave significant data gaps

Clinical Reality: Vital signs are dynamic indicators of health, and sudden changes may signal infection, hemorrhage, shock, or adverse treatment reactions. Traditional spot-checking methods simply cannot capture the real-time changes needed for optimal patient safety.

Professional Guidelines Supporting Continuous Monitoring

American Animal Hospital Association (AAHA) 2020 Guidelines advocate for uninterrupted observation to promptly address complications during the recovery phase.

American College of Veterinary Anesthesiologists (ACVA) 2025 Guidelines reinforce the need for continuous monitoring throughout recovery, emphasizing critical parameters including:

Heart rate (HR) monitoring
Respiratory rate (RR) assessment
Oxygen saturation (SpO₂) tracking
Blood pressure (BP) measurement
Temperature monitoring

Limitations of Traditional Veterinary Monitoring Methods

Current methods for measuring vital signs require physical contact and manual effort, creating multiple problems for veterinary practices:

Temperature Monitoring Issues:

Rectal thermometers require handling and stress patients
Aural devices need patient cooperation and proper positioning
Contact methods interrupt rest periods essential for recovery

Respiratory Rate Assessment Problems:

Visual observation is subjective and intermittent
Capnography requires intubation and equipment attachment
Manual counting interrupts patient rest and recovery

Pulse Monitoring Limitations:

Stethoscope assessment requires trained staff availability
Telemetry systems use leads that can fall off or tangle
Palpation methods stress patients and provide only snapshot data

Patient Safety and Workflow Issues

Equipment-Related Risks:

Leads and attachments can be chewed or tangled
Device malfunction creates safety hazards
Patient movement can dislodge monitoring equipment
Staff injury risk from fractious patients during handling

Staffing and Efficiency Challenges:

10-15 minute monitoring intervals require constant staff attention
Manual data recording increases documentation time
Night shift monitoring often has reduced staffing levels
Critical gaps occur during shift changes and emergencies

Advanced Technology: The VETGuardian® Monitoring System

The VETGuardian device represents a breakthrough in veterinary patient monitoring, utilizing advanced sensor fusion technology to provide continuous vital signs monitoring without patient contact.

Core Technology Components:

Continuous Wave Doppler Radar: Detects heart and lung activity through non-contact signal acquisition
Infrared Thermography: Radiation-free surface temperature detection for inflammation monitoring
LiDAR Technology: Uses pulsed lasers for precise motion detection unaffected by lighting conditions
RGB Camera Integration: Provides 24/7 video monitoring for behavioral assessment
Artificial Intelligence: Real-time data analysis and pattern recognition

VETGuardian System Capabilities

Vital Signs Monitoring:

Heart rate tracking every five minutes with continuous assessment
Respiratory rate monitoring through non-contact signal detection
Temperature measurement via infrared thermography technology
Activity level assessment through motion detection algorithms

Advanced Features:

Smartphone accessibility for remote monitoring capabilities
Multi-device compatibility with laptops and computer systems
Real-time data collection eliminates monitoring gaps
Automated documentation reduces manual recording requirements

Evidence-Based Benefits of Continuous Monitoring

Human Medicine Validation: The TRaCINg feasibility trial demonstrated that patients receiving continuous remote monitoring experienced:

Fewer unplanned critical care admissions
Shorter hospital stays compared to intermittent monitoring
Earlier intervention for developing complications

Veterinary Medicine Evidence: A 2023 validation study of the VETGuardian device showed equal or superior accuracy compared to traditional contact monitoring devices, reinforcing the value of non-invasive continuous monitoring in veterinary patients.

Anesthesia Patient Safety Foundation (APSF) Conclusions: Professional analysis concluded that spot checks are inadequate for patient safety, advocating for continuous electronic monitoring to improve outcomes, especially for patients receiving postoperative medications.

Clinical Benefits for Veterinary Practices

Patient Safety Improvements:

Real-time distress detection enables immediate intervention
Early deterioration identification prevents critical complications
Reduced handling stress improves patient comfort and recovery
Continuous surveillance eliminates dangerous monitoring gaps

Practice Efficiency Enhancements:

Automated data collection reduces staff workload
Remote access capability enables off-site monitoring
Reduced bite risk with fractious patients through contactless monitoring
Staff time optimization for other critical care activities

Quality of Care Advancement:

Increased monitoring accuracy minimizes human error
Personalized care protocols based on continuous data trends
Improved treatment efficacy through timely intervention
Enhanced client confidence in advanced care capabilities

Implementation Benefits for Veterinary Practices

Staffing Efficiency: The VETGuardian® monitoring system eliminates the need for constant physical patient checks, allowing staff to focus on other critical care activities while maintaining comprehensive patient surveillance.

Overnight Monitoring Solutions: Particularly valuable for overnight stays and isolation ward patients, the system provides continuous monitoring without requiring constant staff presence, improving both patient care and operational efficiency.

Risk Reduction:

Eliminates wake-up effect from frequent patient handling
Reduces staff injury risk from aggressive or fearful patients
Prevents equipment displacement through contactless monitoring
Minimizes cross-contamination in isolation situations

The Future of Veterinary Patient Monitoring

Emerging Technology Trends

Artificial Intelligence Integration: Advanced AI algorithms continue improving pattern recognition and predictive capabilities, enabling earlier intervention and more precise patient assessment.

Sensor Technology Advancement: Next-generation sensors provide even greater accuracy and expanded monitoring parameters while maintaining the non-contact advantages of current systems.

Connectivity and Integration: Enhanced integration with practice management systems and electronic medical records streamlines documentation and improves workflow efficiency.

Professional Standards Evolution

Guideline Development: Professional organizations increasingly emphasize continuous monitoring standards, making advanced systems like VETGuardian device essential for maintaining best practice compliance.

Accreditation Requirements: Hospital accreditation programs may soon require continuous monitoring capabilities for certain patient categories, making early adoption strategically advantageous.

Taking Action: Transform Your Practice Monitoring Capabilities

Why Choose the VETGuardian Monitoring System

Proven Technology Advantages:

✓ Non-contact monitoring eliminates patient stress and handling risks
✓ Continuous data collection provides comprehensive patient surveillance
✓ Advanced sensor fusion delivers superior accuracy and reliability
✓ Remote accessibility enables monitoring from any location
✓ Professional validation through peer-reviewed research studies
✓ Easy integration with existing practice workflows
✓ Comprehensive training and ongoing technical support
✓ Competitive differentiation through advanced care capabilities

Ready to Enhance Your Patient Monitoring Standards?

Don’t let traditional monitoring gaps compromise patient safety during critical recovery periods. Join progressive veterinary practices implementing continuous monitoring technology for superior patient outcomes and practice efficiency.

LEARN MORE

09/12/2025

ecallenPost-OpVETGuardian PLUS

Veterinary Monitoring Equipment for BOAS Surgery: Post-Operative Care Solutions

Based on clinical insights from Dr. Shadi Ireifej’s webinar on Brachycephalic Airway Syndrome*

Brachycephalic obstructive airway syndrome (BOAS) affects up to 100% of certain flat-faced dog breeds, making post-operative monitoring critical for successful outcomes. With complication rates ranging from 0-29.5%, veterinary practices need advanced monitoring solutions to detect respiratory distress early and prevent life-threatening complications. The VETGuardian® remote monitoring system is transforming how veterinary professionals manage these challenging respiratory cases.

Understanding BOAS: A Complex Veterinary Challenge

Canine brachycephalic obstructive airway syndrome represents multiple anatomical abnormalities requiring specialized post-surgical monitoring protocols. This multifaceted condition demands continuous respiratory assessment to ensure optimal recovery outcomes.

Primary BOAS Conditions Requiring Monitoring

Upper Airway Abnormalities:

Elongated soft palate: 62-100% incidence rate
Stenotic nares: Affects 17-94% of brachycephalic dogs
Hypoplastic trachea: Present in 11-46% of cases
Nasopharyngeal stenosis: Nasal turbinate abnormalities in 20-100%

Secondary Complications:

Everted laryngeal saccules: Develops in 39-87% of patients
Laryngeal collapse: Progressive condition affecting up to 53%
Everted tonsils: Occurs in 5-56% of cases

These interconnected abnormalities create a cascade of breathing difficulties that require precise post-operative respiratory monitoring to prevent life-threatening complications.

Post-Surgical Monitoring Challenges in BOAS Cases

Complex Anatomical Considerations

Brachycephalic breeds present unique monitoring challenges due to their distinctive anatomy:

Structural Abnormalities Affecting Monitoring:

Shortened skull length with wider configuration
Smaller glottic index and elliptical larynx shape
Reduced nasopharynx dimensions
Longer, thicker soft palate positioned more caudally
Macroglossia (enlarged tongue)
Decreased buccal opening

Breathing Pattern Complications:

Slow inspirations with rapid expiratory phases
Open mouth breathing dependency
Increased respiratory noise generation
Temperature regulation difficulties

Post-Surgical Respiratory Risks

BOAS surgery recovery presents specific monitoring challenges that require continuous assessment:

Immediate Complications (0-29.5% incidence):

Laryngeal swelling and inflammation
Noncardiogenic pulmonary edema
Bronchopneumonia development
Respiratory distress episodes
Hemorrhage and incisional dehiscence
Voice changes and regurgitation

Critical Monitoring Parameters:

Respiratory rate patterns and effort assessment
Temperature regulation monitoring
Activity level and exercise tolerance
Pain indicators affecting breathing patterns

Traditional Veterinary Monitoring Limitations

Manual Assessment Challenges

Stress-Induced Complications: Traditional hands-on monitoring can exacerbate breathing difficulties in BOAS patients who are already compromised by:

Increased anxiety from frequent handling
Elevated respiratory rates during examination
Temperature elevation from stress
Potential for respiratory crisis during restraint

Intermittent Data Collection Issues:

Spot-checking limitations: Brief assessments miss breathing pattern changes
Subjective interpretations: Manual monitoring varies between staff members
Sleep disruption: Essential rest periods interrupted for vital sign checks
Documentation gaps: Inconsistent recording of respiratory parameters

Staffing Resource Constraints: Many veterinary practices struggle with 24/7 monitoring capabilities, creating dangerous gaps during critical recovery periods when respiratory complications often develop.

Advanced Solutions: The VETGuardian Monitoring System

Telediagnostics is a rapidly emerging and powerful tool evolving in the veterinary space. The VETGuardian telediagnostic device by Zomedica addresses BOAS-specific challenges with continuous monitoring capabilities designed for respiratory assessment.

Touchless Monitoring Technology

Continuous Vital Sign Detection: The VETGuardian system continuously monitors body temperature, pulse rate and respiratory rate with thermal cameras and doppler technology, and monitors movement via video camera.

Key Technology Features:

Doppler radar technology: Precise respiratory measurements without patient contact

Thermal imaging: Continuous temperature monitoring critical for brachycephalic heat regulation

Video surveillance: Visual breathing pattern assessment

Multi-patient capability: Multiple animals can be monitored simultaneously

Clinical Advantage: Measuring vital parameters while eliminating patient physical contact minimizes patient stress and anxiety—essential for BOAS patients who struggle with breathing under normal conditions.

Professional Implementation Benefits

Practice Efficiency Improvements:

Monitor multiple BOAS recovery patients simultaneously
Reduce staffing requirements for overnight monitoring
Eliminate stress-induced complications from frequent handling
Provide objective data for clinical decision-making

Enhanced Patient Care:

Continuous respiratory pattern analysis
Early detection of breathing effort changes
Real-time temperature regulation monitoring
Comprehensive activity level assessment

VETGuardian System vs Traditional BOAS Monitoring

Advanced Features for Respiratory Care

Continuous Assessment Capabilities

Doppler Technology Applications:

Respiratory rhythm irregularity detection
Breathing effort quantification monitoring
Rest vs. active breathing pattern comparisons
Sleep-disordered breathing identification

Thermal Camera Benefits:

Continuous temperature regulation assessment
Heat stress detection in brachycephalic breeds
Inflammation monitoring around surgical sites
Activity level correlation with temperature changes

Custom Alert Systems for BOAS Cases

Respiratory-Specific Monitoring Alerts:

Respiratory rate threshold notifications
Breathing pattern irregularity warnings
Temperature elevation alerts
Activity level decrease indicators

Professional Protocol Integration:

Immediate notifications for critical parameter changes
Tiered alert systems for different severity levels
Integration with on-call veterinarian communication systems
Automated documentation of alert events and responses

The Future of Advanced Respiratory Monitoring

Discover how the VETGuardian device can transform your BOAS surgery outcomes and practice efficiency. Our veterinary technology specialists understand the unique challenges of respiratory monitoring and are ready to help you implement this breakthrough solution.

Visit zomedicadev.com to explore the VETGuardian system’s respiratory monitoring capabilities! The future of brachycephalic airway surgery monitoring is here—continuous, stress-free, and more precise than traditional methods.

*Dr. Ireifej was paid by Zomedica, Inc. to present this webinar

LEARN MORE

09/01/2025

ecallenTRUVIEW

Veterinary Cardiac Testing: Advanced Heart Disease Diagnostics Equipment

Based on clinical insights from Dr. Gary Oswald’s webinar, When the Heart Cries for Help. Using NT-proBNP in Canine Cardiac Disease*

Heart disease affects millions of dogs and cats, yet most cases go undetected until patients present in crisis. Studies show that many cardiac conditions remain hidden for months or years before becoming clinically apparent, often making their first appearance as sudden death or acute heart failure. The TRUFORMA® diagnostic system revolutionizes veterinary cardiac care by bringing advanced heart disease testing directly into general practice, enabling early detection and better patient outcomes through rapid NT-proBNP cardiac biomarker analysis.

The Hidden Epidemic: Heart Disease in Veterinary Practice

Heart disease represents one of the most challenging diagnostic areas for general practitioners, with traditional methods often failing until disease reaches advanced stages.

Common Diagnostic Challenges:

Physical examination may appear normal in early disease stages
Heart murmurs can be absent in many cardiomyopathy cases
Chest radiographs often show no changes until heart failure develops
ECG abnormalities frequently absent in subclinical patients
Patient stress during examination masks subtle signs

Clinical Reality: Many pets with significant heart disease show no obvious symptoms during routine wellness visits, leaving veterinarians without clear indicators to pursue cardiac evaluation.

The Cost of Late Detection

Patient Impact:

First symptom often sudden death or acute heart failure
Advanced disease requires more aggressive, expensive treatment
Shorter lifespan and reduced quality of life
Limited treatment options once heart failure develops

Practice Impact:

Emergency presentations requiring immediate referral
Client dissatisfaction when disease “appears suddenly”
Missed opportunities for preventive care
Higher liability risk from undiagnosed conditions

How to Diagnose Heart Disease in Dogs and Cats

Subtle Symptoms Pet Owners Report:

Exercise intolerance or tiring more easily during walks
Heavy breathing during normal activities
Restlessness at night or difficulty settling
Coughing episodes especially at night or early morning
Decreased appetite or reluctance to eat
Weight loss despite normal eating habits

Clinical Signs for Veterinarians:

Soft heart murmurs that may be intermittent
Increased respiratory effort during examination
Pale or slow capillary refill indicating poor circulation
Weak pulses or pulse deficits
Behavioral changes such as hiding or decreased activity

Traditional Diagnostic Limitations

Physical Examination Challenges: While cardiac auscultation remains important, many patients with significant heart disease present with normal or only subtle examination findings, particularly cats with cardiomyopathies and dogs with early dilated cardiomyopathy.

Radiographic Limitations: Chest X-rays frequently appear normal in subclinical cardiac patients. Even when abnormalities are present, distinguishing cardiac from respiratory causes can be challenging, especially in emergency situations.

The Diagnostic Gap: General practitioners need reliable tools to identify cardiac disease before clinical signs develop, allowing for early intervention and improved patient outcomes.

Advanced Heart Disease Testing: The NT-proBNP Solution

NT-proBNP (N-terminal pro-B-type natriuretic peptide) serves as the heart’s “cry for help,” providing objective evidence of cardiac stress when traditional diagnostic methods fall short.

How Cardiac Biomarkers Work: When the heart experiences stress from increased pressure or volume, cardiac cells produce a hormone called pro-BNP. This molecule is then split into two parts:

Active BNP: Helps the body manage cardiac stress by promoting blood vessel dilation and kidney function
NT-proBNP: Inactive fragment that remains in the bloodstream longer and can be easily measured

Clinical Advantage: NT-proBNP levels rise significantly before clinical signs appear, enabling early detection of heart disease in apparently healthy patients.

Why NT-proBNP Testing Transforms General Practice

Immediate Clinical Applications:

Emergency triage of patients with breathing difficulties
Pre-anesthetic screening for high-risk patients

Wellness screening in breeds prone to heart disease
Treatment monitoring for patients with known cardiac conditions

Practice Benefits:

15-minute results for immediate clinical decision-making
Objective data to support clinical findings

Client confidence in advanced diagnostic capabilities

Early intervention opportunities improving patient outcomes

Signs of Heart Failure in Pets: When to Test

Dogs Presenting with Breathing Difficulties: Emergency differentiation between heart and lung problems is critical for appropriate treatment. Traditional methods often leave uncertainty in diagnosis.

Common Emergency Presentations:

Labored breathing with or without coughing
Exercise intolerance or collapse during activity
Loud heart murmurs in breeds not typically affected
Distended abdomen potentially indicating heart failure
Anxiety or restlessness especially at night

NT-proBNP Reference Values for Dogs:

Below 900 pmol/L: Respiratory cause likely, heart failure unlikely
Above 2500 pmol/L: Congestive heart failure probable
900-2500 pmol/L: Consider pulmonary hypertension, pursue cardiac evaluation

Cat Heart Problems: Silent Disease Detection

Feline Cardiac Disease Challenges: Cats excel at hiding cardiac disease, often showing no symptoms until presenting in acute heart failure or sudden death.

When to Suspect Feline Heart Disease:

Any heart murmur detected during examination
Breathing difficulties or open-mouth breathing
Sudden onset of rear limb paralysis
Hiding behavior or decreased activity
Poor appetite or weight loss

NT-proBNP Reference Values for Cats:

Below 100 pmol/L: Heart disease unlikely
Above 300 pmol/L: Significant cardiac disease probable
Special consideration: All cats with heart murmurs should receive NT-proBNP testing

TRUFORMA® Diagnostic System: Revolutionary Point-of-Care Testing

The TRUFORMA diagnostic system brings laboratory-quality cardiac testing directly into veterinary clinics, providing rapid, accurate results that guide immediate treatment decisions.

Key Technology Features:

Bulk acoustic wave technology eliminates interference from hemolysis or lipemia
15-20 minute results for immediate clinical decision-making
Self-contained cartridges require no reagent preparation
Multiple test capabilities beyond cardiac biomarkers

Clinical Advantages:

Sample flexibility: Works with both plasma and serum
Minimal training required for operation
Compact design fits in any clinic setting
Proven accuracy with correlation >0.95 to reference laboratories

TRUFORMA System vs. Send-Out Testing

Breed-Specific Cardiac Screening Guidelines

High-Risk Canine Breeds

Dilated Cardiomyopathy-Prone Breeds:

Doberman Pinschers: Special consideration with lower threshold (700 pmol/L)
Great Danes: Standard screening protocols
Irish Wolfhounds: Annual screening recommended
Standard Schnauzers: Begin screening at 4-5 years
Boxers: Monitor for both DCM and arrhythmogenic cardiomyopathy

Breed-Specific Considerations: Labrador Retrievers, Newfoundlands, Greyhounds: May have elevated NT-proBNP values (>900 pmol/L) even with normal hearts. Pursue cardiac evaluation but normal echo findings are not uncommon in these breeds.

High-Risk Feline Breeds

Hypertrophic Cardiomyopathy-Prone Breeds:

Maine Coons: Begin screening at 2-3 years
Ragdolls: Annual testing recommended
Sphynx cats: High predisposition requires early screening
British Shorthairs: Include in routine wellness protocols
Persians: Consider screening all breeding animals

Universal Feline Screening: Given the difficulty in detecting feline heart disease through examination alone, many specialists recommend annual NT-proBNP screening for all adult cats as part of routine wellness care.

Ready to Transform Your Heart Disease Detection?

Don’t let cardiac disease hide in your patients until emergency situations develop. Implement advanced cardiac testing to provide early detection, accurate emergency triage, and comprehensive patient management throughout the disease process.

Visit zomedicadev.com to explore the TRUFORMA diagnostic system’s cardiac testing capabilities and discover how advanced heart disease detection can enhance your practice’s patient care standards while improving diagnostic confidence and practice profitability.

*Dr. Oswald was paid by Zomedica, Inc. for his webinar presentation

LEARN MORE

08/20/2025

ecallenTRUVIEW

Modern Dermatology Labs: Essential Techniques for Today’s Veterinary Practice

Key insights from Dr. Robert Schick’s recent webinar on small animal dermatology diagnostics.*

Veterinary dermatology has evolved dramatically over the past four decades, and so have our diagnostic tools. In a recent webinar, Dr. Robert Schick, DVM, DACVD, shares critical insights on what’s changed—and what remains essential—in dermatology laboratory techniques. Just as modern cars require different tools than classic vehicles, today’s dermatology cases demand both traditional skills and cutting-edge technology.

The Modern Approach: Dr. Schick's Philosophy

Dr. Schick demonstrates that modern veterinary dermatology isn’t about choosing between old and new—it’s about strategically combining time-tested techniques with advanced tools to deliver superior patient care and diagnostic accuracy.

Success requires:

Mastering fundamentals while embracing innovation
Prioritizing consistency over perfect technique
Leveraging digital systems to reduce variability
Utilizing point-of-care testing for faster diagnoses
Proper sample handling regardless of testing method

Skin Scrapings: Dr. Schick's Refined Technique

Despite revolutionary parasiticides like isoxazolines dramatically reducing mite cases, Dr. Schick emphasizes that proper scraping technique remains crucial for accurate diagnosis.

Essential steps Dr. Schick teaches:

Gently squeeze skin before scraping
Scrape until capillary oozing occurs
Use skin spatulas instead of blades for safety (around $6)
Scan at 4X power initially

Monitoring treatment success: Dr. Schick explains that understanding mite life stages is key. Finding dead adults after 4 weeks indicates effective treatment, while continued eggs and larvae suggest therapy adjustment is needed.

Cytology: Dr. Schick's Most Valuable Diagnostic Tool

The Consistency Challenge
While diff-quick remains the gold standard, Dr. Schick emphasizes that consistency matters more than perfect technique.

Common pitfalls Dr. Schick identifies:

Using frosted tape instead of clear tape for preparations
Inconsistent staining protocols
Variable heat-fixing methods

Ear Cytology vs. Cultures: Why Dr. Schick Chooses Cytology

Dr. Schick strongly advocates for cytology over cultures in ear cases:

“I have not cultured an ear in so many years I couldn’t even tell you how many.” —Dr. Schick

Dr. Schick’s reasoning:

External ear cultures are often misleading
Sensitivity patterns based on blood levels don’t reflect topical concentrations
Multiple ear sites yield different culture results
Cytology provides immediate, actionable information

Digital Microscopy Revolution: Dr. Schick Champions The TRUVIEW™ Microscope

The Game Changer for Consistency: Traditional cytology faces a major challenge: technician variability in staining. Dr. Schick demonstrates how Zomedica’s fully automated digital microscope, TRUVIEW™, solves this problem.

Benefits Dr. Schick highlights:

Automated, consistent staining with 5-minute processing time
Standardized slide preparation eliminating human error
Superior documentation for medical records
Easy image sharing with clients and referring veterinarians
Remote consultation capabilities

“This takes all of that variability out,” Dr. Schick notes, highlighting how the system removes human error from the diagnostic process.

Point-of-Care Revolution: Dr. Schick's TRUFORMA® Platform Success Stories

Dr. Schick showcases how Zomedica’s TRUFORMA® diagnostic platform has transformed in-house diagnostics for dermatology cases:

Thyroid Testing Breakthrough

Accurate canine TSH levels (previously impossible in-house)
Total T4 and Free T4 testing with 30-minute results vs. overnight shipping

Adrenal Function Assessment

ACTH measurements for Cushing’s screening
25-minute results vs. 8-hour dexamethasone suppression tests

Real case impact: Dr. Schick shares how TRUFORMA diagnosed hypothyroidism in a Cocker Spaniel when the owner’s suspicion proved correct—elevated TSH and unmeasurable T4 confirmed the diagnosis, leading to successful treatment.

Dermatopathology Excellence: Dr. Schick's Biopsy Guidelines

Dr. Schick emphasizes that proper biopsy technique dramatically impacts diagnostic accuracy:

Critical Guidelines:

Never scrub lesions before biopsy
Use 6-8mm disposable punches (not 2-4mm)
Handle samples gently at the base
Request dermatopathology-trained pathologists

Dr. Schick’s Top Mistakes to Avoid:

Reusing disposable punches instead of using fresh ones
Grabbing biopsy centers with forceps causing tissue damage
Scrubbing away diagnostic surface material before sampling
Using inadequate punch sizes that limit diagnostic capability
Failing to request specialized pathologists for dermatology cases

Key Takeaways for Modern Practice

Dr. Schick’s comprehensive approach demonstrates that the practices that thrive will be those that maintain diagnostic fundamentals while leveraging technology to overcome traditional limitations like staining variability and lengthy turnaround times.

Essential points from Dr. Schick’s webinar:

Consistency in technique matters more than perfection
Digital microscopy eliminates human variability in cytology
Point-of-care testing provides immediate, actionable results
Proper biopsy technique is non-negotiable for accurate diagnosis
Modern dermatology combines proven methods with advanced technology

Dr. Schick’s bottom line: Today’s dermatology diagnostics combine proven techniques with advanced technology. Success comes from mastering fundamentals while strategically embracing innovations that solve real diagnostic challenges.

Ready to modernize your dermatology diagnostics? Visit Zomedica.com to learn more about TRUVIEW digital microscopy and TRUFORMA point-of-care testing solutions from Zomedica.

*Dr. Schick was paid by Zomedica, Inc. for his educational webinar.

LEARN MORE

08/20/2025

ecallenVETGuardian PLUS

Emergency Splenic Mass Surgery: Critical Insights for Veterinary Practice

Key takeaways from Dr. Shadi Ireifej’s comprehensive webinar on acute non-traumatic spontaneous hemoperitoneum.

When a large breed dog presents in hemorrhagic shock with a distended abdomen, every second counts. In his recent webinar for veterinary professionals, Dr. Shadi Ireifej, DVM, DACVS, delivers crucial insights for managing these critical cases—from initial diagnostics through post-operative monitoring.

The Reality Check: It's Usually Cancer, But Not Always

Dr. Ireifej presents sobering statistics: splenic masses account for 3-5% of all cancers in dogs over 8 years, with malignancy rates of 64-80%. While hemangiosarcoma dominates these cases, he emphasizes a critical point: you cannot definitively diagnose malignancy without complete splenectomy and histopathology.

“Even when hepatic nodules appear on ultrasound alongside a splenic mass, benign disease remains possible. This uncertainty makes honest client communication essential.” —Dr. Ireifej

Setting Realistic Expectations: Dr. Ireifej's Prognosis Guidelines

Understanding survival statistics helps guide both surgical decisions and client discussions:

Hemangiosarcoma Prognosis:

Stage 1: ~151 days | Stage 2: ~107 days | Stage 3: ~73 days
Surgery alone: ~2 months | Surgery + chemotherapy: ~172 days

Benign Disease: Essentially curative with excellent long-term survival (85% at one year)

Diagnostic Priorities: What Dr. Ireifej Focuses On

CBC Red Flags That Guide Decisions
Dr. Ireifej identifies thrombocytopenia in 75% of hemoperitoneum cases, often causing surgical hesitation. He explains: “I believe the thrombocytopenia is due to acute hemorrhage and not necessarily a coagulopathy per se.”

Red flags Dr. Ireifej watches for:

Leukocytosis with neutrophilia
Non-regenerative anemia with schistocytes
Ventricular arrhythmias (25-45% of hemangiosarcoma cases)

Dr. Ireifej’s Smart Imaging Strategy
Don’t delay surgery for extensive imaging in time-sensitive cases. Dr. Ireifej does insist on thoracic radiographs to detect cardiac silhouette changes, pleural effusion, metastatic disease, and sternal lymphadenopathy.

Dr. Ireifej's Emergency Splenectomy Protocol

The Non-Negotiable: Complete Splenectomy Always
Dr. Ireifej takes a firm stance: partial splenectomy for splenic masses is unethical and inappropriate. The high cancer probability makes complete removal mandatory.

Essential surgical steps:

Complete splenectomy hugging the splenic capsule
Liver biopsy for staging (always performed)
Consider concurrent procedures only if patient stability allows

Innovation in Hemostasis: VETIGEL® Hemostatic Gel

Dr. Ireifej enthusiastically demonstrates Zomedica’s VETIGEL® hemostatic gel for managing surgical bleeding during liver biopsies:

Rapid hemostasis (maximum 2 minutes)
No manual pressure required
Absorbable and safe if ingested

“This thing is awesome. It addresses the nervousness many surgeons feel about liver biopsies.” —Dr. Ireifej

Revolutionary Post-Op Monitoring: Dr. Ireifej Champions the VETGuardian® Monitor

Traditional monitoring relies on frequent patient handling, but Dr. Ireifej highlights how Zomedica’s VETGuardian® system transforms patient care through touchless monitoring.

Key capabilities:

Thermal imaging for body temperature
Pulse and respiratory rate detection
Patient movement tracking
Centralized monitoring for multiple patients

“I do believe that telemedicine diagnostics are the future. Devices like this are where it’s at.” —Dr. Ireifej

Ideal for: Post-splenectomy cases, pyometra recovery, brachycephalic patients, and any critical case requiring intensive monitoring without wire attachment.

Dr. Ireifej’s Post-Operative Protocol
First 24 Hours:

Continuous or 6-hourly ECG monitoring
Blood pressure checks every 6 hours
PCV/total solids within 1 hour, then twice daily
Sternal recumbency to prevent aspiration pneumonia

Arrhythmia Management: Treat if patient shows clinical signs OR if >30% of ECG strip shows ventricular arrhythmias using lidocaine bolus followed by CRI, or procainamide IM transitioning to oral.

Dr. Ireifej's Top Mistakes to Avoid

Delaying surgery for extensive imaging workups
Attempting partial splenectomy for any splenic mass
Skipping liver biopsy during exploratory surgery
Inadequate post-operative monitoring of cardiac rhythms
Promising definitive diagnosis before histopathology results

Key Takeaways for Practice Success

Dr. Ireifej’s message is clear: successful splenic mass emergency management requires combining surgical expertise with advanced monitoring technology. Tools like the VETGuardian Remote Monitor represent the evolution toward sophisticated, less invasive patient monitoring that improves outcomes while reducing stress.

Essential points:

Time is critical—stabilize quickly and proceed to surgery
Complete splenectomy is mandatory for any splenic mass
Histopathology provides the only definitive diagnosis
Advanced monitoring technology significantly improves outcomes
Honest client communication about uncertainty until biopsy results arrive

For practices regularly handling emergency cases, Dr. Ireifej advocates investing in touchless monitoring technology and advanced hemostatic products to enhance both surgical success rates and client satisfaction.

Visit Zomedica.com to learn more about how the VETGuardian remote monitoring system and VETIGEL hemostatic gel can enhance your emergency surgery outcomes.

LEARN MORE

07/28/2025

ecallenEquine HealthTRUFORMA

How the TRUFORMA® Point of Care Platform Transformed Diagnostics for Metamora Equine: A Veterinarian’s Perspective

Veterinary professionals know that time, accuracy, and confidence in diagnostics can directly impact patient outcomes. At Zomedica, our mission is to empower veterinarians with innovative tools that deliver precise, timely insights at the point of care.

We recently received an outstanding review from Roland Thaler, VMD, DACVSMR, Cert. ISELP, of Metamora Equine PC, who integrated the TRUFORMA® diagnostic platform into his equine veterinary practice. What follows is his real-world perspective on how TRUFORMA’s equine-specific assays—particularly the insulin assay for equine plasma and the endogenous ACTH (eACTH) assay—have elevated his diagnostic capabilities and enhanced clinical decision-making.

Reliable Diagnostic Accuracy That Builds Clinical Confidence

Dr. Thaler was immediately struck by the exceptional accuracy of the TRUFORMA platform.

“The device leverages advanced technology to provide precise and reliable results, ensuring that every diagnosis is grounded in confidence.”

In his practice, this reduction in equivocal results has been a game-changer—enabling faster treatment decisions and ultimately improving patient outcomes. This level of diagnostic confidence has strengthened his trust in point-of-care testing (POCT) and supports his ability to deliver high-quality, informed care.

Seamless Workflow Integration for Equine Practice

The TRUFORMA device’s intuitive user interface, efficient workflow, and compact design helped it fit seamlessly into Dr. Thaler’s daily operations.

“The device’s design is both intuitive and elegant. The touchscreen interface and clear step-by-step instructions make the testing process simple.”

He highlighted the streamlined sample preparation and analysis, which reduce turnaround times and minimize the risk of user error—crucial in busy or mobile veterinary settings.

“The compact footprint of the TRUFORMA device fits perfectly even in the space-constrained requirements of ambulatory practice.”

Rapid Results for Faster Treatment Decisions

One of the key advantages of the TRUFORMA device is its ability to deliver accurate diagnostic results in real-time, allowing for quicker interventions and better client communication.

“This quick turnaround has allowed me to make timely treatment decisions, improving client communication and satisfaction.”

Especially in equine medicine, where early diagnosis is often essential, Dr. Thaler notes that clients value the immediate answers about their horse’s metabolic health.

Exceptional Veterinary Support from the Zomedica Team

In addition to the technology, Dr. Thaler emphasized the value of Zomedica’s customer support team:

“Zomedica’s customer support is another standout feature. Their team is responsive, knowledgeable, and genuinely invested in ensuring that practices get the most out of their TRUFORMA device.”

A Clear Endorsement from a Veterinary Specialist

After seeing the impact of the TRUFORMA platform firsthand, Dr. Thaler strongly recommends the platform to other veterinary professionals:

“Zomedica’s TRUFORMA device has exceeded all my expectations. Its combination of precision, innovation, and practicality makes it a game-changer in veterinary diagnostics.”

“I wholeheartedly recommend the TRUFORMA Diagnostic System to any veterinary professional seeking to elevate their standard of care. It’s an investment that pays dividends in improved diagnostics, client trust, and better patient outcomes.”

Why Choose the TRUFORMA® Platform for Your Veterinary Practice?

The TRUFORMA platform is a state-of-the-art diagnostic platform designed for in-clinic testing of multiple biomarkers, with assays tailored to the needs of canine, feline, and equine patients. With advanced bulk acoustic wave (BAW) technology, the TRUFORMA device delivers reference laboratory-quality results at the point of care – accurately, quickly and reliably.

Whether you’re in a clinic or out in the field, the TRUFORMA platform helps veterinary professionals:

Improve diagnostic precision
Streamline workflows
Deliver faster care decisions
Increase client satisfaction

Ready to See What the TRUFORMA® Platform Can Do for You?

Discover how the TRUFORMA platform can revolutionize diagnostics in your practice. Explore the platform or connect with our team to schedule a demo.

LEARN MORE